🚨 #ESMOGI2025 Poster! TEOGIC study in Spain: early-onset GI cancer has its own biology. Sex differences, protein markers, lifestyle data ▶️  Watch now bit.ly/4eJaOOa #MediMix #EOCRC #GICancer #YoungSurvivors

📊 #ESMOGI2025 Poster! Rectal cancer <50 = more advanced stage, more symptoms Dr @CedricSchraepen's data from UZ Leuven. ▶️ Watch now bit.ly/4eJaOOa #MediMix #EOCRC #ColorectalCancer #YoungAdults

🧠 #ESMOGI2025 Poster! Choline PET/CT = no added value vs MRI or FDG PET/CT Dr Couvert presents HCC imaging data ▶️ Watch now bit.ly/4eJaOOa #MediMix #HCC #LiverCancer #Imaging

⚖️ #ESMOGI2025 Poster! Tislelizumab vs Nivo vs Pembro in GC Network meta-analysis shows comparable efficacy with TIS ▶️ Watch now bit.ly/4eJaOOa #MediMix #GastricCancer #Immunotherapy #PD1

📈 #ESMOGI2025 Poster! 19.1 mo OS in ESCC w/ TAP ≥5% Tislelizumab + chemo shows strong survival signal ▶️ Watch now bit.ly/4eJaOOa #MediMix #ESCC #Tislelizumab #CheckpointInhibitors

🧬#ESMOGI2025 Poster! Only 2% of GEP-NET patients meet Milan criteria for liver transplant Missed opportunities? Dr @ManonVerhe explains ▶️ Watch now bit.ly/4eJaOOa #MediMix #NETs #LiverTransplant #Oncology

🧪#ESMOGI2025 Poster! Dr @WLybaert shares factors tied to long survival on Nal-IRI 🎯 Dose adjustment & liver mets matter ▶️ Watch now bit.ly/4eJaOOa #MediMix  #PancreaticCancer #RealWorldData

📢 #ESMOGI2025 In Depth! NALLONG study: exceptional responders on nal-IRI in mPDAC. Prof Van Laethem explores real-world survival & dose adjustments. 👀 Watch now bit.ly/4eJaOOa #MediMix #PancreaticCancer #Oncology

🔥 #ESMOGI2025 In Depth! DiCE CEO Zorana Maravic highlights the rising burden of early-onset CRC and urges systemic change for timely diagnosis, fertility preservation and age-appropriate support. 👀 Watch now bit.ly/4eJaOOa #MediMix #EOCRC #PatientVoice

📢 #ESMOGI2025 In Depth! Prof @LorenzaRimassa & Dr @WLybaert on STRIDE in the real world: frail HCC patients included. SIERRA shows safety maintained despite poor ECOG/liver function. 👀 Watch now bit.ly/4eJaOOa #MediMix #HCC #LiverCancer #Immunotherapy

📢 #ESMOGI2025 In Depth! Prof Möhler & Prof Van Cutsem discuss RATIONALE-305 and PD-L1 TAP scoring in tislelizumab-treated patients. 👀 Watch now bit.ly/4eJaOOa #MediMix #Oncology #GastricCancer

🎥 #EHA2025 Poster! Dr @YStepanishyna shows that better cognitive function and self-image predict return to work after allo-HSCT. ✅ Mental health = key to long-term recovery. 👀 Watch now 👉 bit.ly/4n8wsz1 #MediMix #AlloHSCT #QoL #Haematology

🎥 #EHA2025 Poster! Zanubrutinib outperforms VenO on PFS in MAIC comparison. ❌ No head-to-head trial (yet). 👀 Watch now 👉 bit.ly/4n8wsz1 #MediMix #CLL #Haematology

🎥 #EHA2025 Poster! 2L axi-cel in LBCL = cost-effective in US models ✅ Driven by long-term OS & event-free gains. 👀 Watch now 👉bit.ly/4n8wsz1 #MediMix #HealthEconomics #Haematology

🧬 #ESMOGI2025 In Depth! Dr @GJRas shares: ✔️ Window of opportunity in neoadjuvant treatment ✔️ Immune tracking via TCR sequencing ✔️ AI-powered pathology insights 👀  Watch now bit.ly/4eJaOOa #MediMix #ColorectalCancer #Oncology #AI #Neoadjuvant

🎥 #EHA2025 Poster! 5-year ZUMA-3 update: ✅ Brexu-cel delivers long-term OS in R/R B-ALL (40% at 5 years). 👀 Watch now 👉bit.ly/4n8wsz1 #MediMix #CAR_T #Haematology

📊 #ESMOGI2025 In Depth! Prof @TimonV & Dr @WLybaert provide real-world evidence. 👀  Watch now bit.ly/4eJaOOa #MediMix #NETs #SSA #Oncology #RealWorldData

🚀 #ESMOGI2025 In Depth! Prof @deroose_c & Prof Haustermans dive into: ✔️ PRRT & novel alpha emitters ✔️ Proton therapy for upper GI cancer ✔️ Synergies with PET imaging 👀  Watch now bit.ly/4eJaOOa #MediMix #Radioligand #ProtonTherapy #Oncology

🎥 #EHA2025 Poster! FYN::TRAF3IP2 fusion linked to neutrophil-rich PTCL-NOS. ✅ New biological insights from mouse models. 👀 Watch now 👉bit.ly/4n8wsz1 #MediMix #Lymphoma #Haematology